ArticleCancer immunology, immunotherapy : CII2006
Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model.
Article in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 80 citations in OpenAlex.
- Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses.NPJ vaccines · 2025Article
- Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity.ACS applied materials & interfaces · 2025Article
- The HPV viral regulatory mechanism of TLRs and the related treatments for HPV-associated cancers.Frontiers in immunology · 2024Review
- HPV-Associated Tumor Eradication by Vaccination with Synthetic Short Peptides and Particle-Forming Liposomes.Small (Weinheim an der Bergstrasse, Germany) · 2021Article
- Combinatorial treatment with polyI:C and anti-IL6 enhances apoptosis and suppresses metastasis of lung cancer cells.Oncotarget · 2017Article
- Article
- Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.Molecular pharmaceutics · 2013Article
- Polyinosinic-cytidylic acid as an adjuvant on natural killer- and dendritic cell-mediated antitumor activities.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses.Cancer immunology, immunotherapy : CII · 2013Article
- Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.Infection and immunity · 2013Article
- The antitumor effect of the toll-like receptor 3 ligand polyinosinic-cytidylic acid as an adjuvant.Cancer immunology, immunotherapy : CII · 2013Article
- Transcutaneous DNA immunization following waxing-based hair depilation elicits both humoral and cellular immune responses.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2012Article
- Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.Journal of medicinal chemistry · 2012Article
- Activation and inhibition of transglutaminase 2 in mice.PloS one · 2012Article
- A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.Human gene therapy · 2011Article
- Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2011Article
- Replicase-based plasmid DNA shows anti-tumor activity.BMC cancer · 2011Article
- Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC.PloS one · 2011Article
- An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines.Journal of drug delivery · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the inherent lack of immunogenicity of peptides, it is generally recognized that the strong inflammatory signals that are required to elicit specific responses against peptide-based therapeutic tumor vaccines may not be provided by the standard/conventional vaccine adjuvants. In this study, we have demonstrated dsRNA in the form of synthetic pI:C as a potent adjuvant to enhance the specific anti-tumor immune responses against a peptide-based vaccine. When complexed with an MHC I-restricted minimal peptide epitope derived from the HPV 16 E7 protein, the resulting pI:C/E7(49-57) molecular complex induced strong E7(49-57)-specific CTL responses that caused significant regressions of model human cervical cancer tumors pre-established in mice. In addition, although the proportion of DCs in tumor-bearing mice was significantly decreased when compared to that in naïve mice, immunization with pI:C/E7(49-57 )restored the proportion of DCs in tumor-bearing mice. Double-stranded RNA may hold a great potential as an adjuvant to induce cellular immune responses for tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.